Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05371093 | Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma(ZUMA-22) | active not recruiting | Phase 3 | 231 | Kite, A Gilead CompanyINDUSTRY | 7 | Oct 15, 2025 | clinicaltrials |
| NCT02909036 | Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. | active not recruiting | Phase 1 | 46 | Memorial Sloan Kettering Cancer CenterOTHER |
| 1 |
| Oct 10, 2025 |
| clinicaltrials |
| NCT05270057 | Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies(LONCA) | active not recruiting | Phase 1 | 11 | Medical College of WisconsinOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT02153580 | Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia | active not recruiting | Phase 1 | 37 | City of Hope Medical CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT05556720 | Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial(BOOST-IC) | active not recruiting | Phase 3 | 960 | Monash UniversityOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT05878184 | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) | active not recruiting | Phase 1 | 16 | Sana BiotechnologyINDUSTRY | 2 | Oct 2, 2025 | clinicaltrials |
| NCT03327597 | Iceland Screens, Treats or Prevents Multiple Myeloma(iStopMM) | active not recruiting | N/A | 80,761 | University of IcelandOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT03147885 | Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 43 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT04479267 | Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma | active not recruiting | Phase 2 | 8 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT04606433 | Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 | 47 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05192486 | A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) | active not recruiting | Phase 1 / Phase 2 | 12 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05485753 | A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) | active not recruiting | Phase 1 / Phase 2 | 7 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05627856 | A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL | active not recruiting | Phase 1 / Phase 2 | 4 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05621096 | Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 33 | University of NebraskaOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05823571 | Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | active not recruiting | Phase 1 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06381141 | A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma | active not recruiting | Phase 1 | 30 | Cullinan Therapeutics Inc.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07176130 | Demographics and Clinical Characteristics of Ocular Inflammatory Diseases in Singapore | active not recruiting | — | 200 | Singapore National Eye CentreOTHER_GOV | 1 | Sep 16, 2025 | clinicaltrials |
| NCT04447716 | An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment | active not recruiting | Phase 1 | 4 | Thomas Jefferson UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT05871008 | Integrated Actionable Aging Assessment for Cancer Patients Pilot | active not recruiting | N/A | 35 | University of Colorado, DenverOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT01863550 | Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 3 | 1,087 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Sep 8, 2025 | clinicaltrials |
| NCT04671693 | A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.(PASCA) | active not recruiting | N/A | 500 | Centre Leon BerardOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05673083 | Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma | active not recruiting | — | 200 | All4CureINDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07154537 | Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM) | active not recruiting | Phase 4 | 101 | National Taiwan University HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT05788081 | Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.(TOP-FLOR) | active not recruiting | Phase 2 | 40 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT04541056 | Goal Management Training for Adult Survivors of Childhood Leukemia and Non-Hodgkins Lymphoma With Neurocognitive Sequelae | active not recruiting | N/A | 60 | Norwegian University of Science and TechnologyOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT03314181 | A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 2 | 156 | AbbVieINDUSTRY | 7 | Aug 14, 2025 | clinicaltrials |
| NCT05308654 | A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets | active not recruiting | Phase 1 | 34 | AbbVieINDUSTRY | 4 | Aug 14, 2025 | clinicaltrials |
| NCT04892667 | Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG(DETECT) | active not recruiting | N/A | 128 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT02734771 | A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)(BV mini CHP) | active not recruiting | Phase 2 | 24 | Patrick ReaganOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT02790515 | Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation | active not recruiting | Phase 2 | 170 | St. Jude Children's Research HospitalOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT03314636 | Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.(CONPET) | active not recruiting | Phase 2 | 53 | Oslo University HospitalOTHER | 3 | Aug 8, 2025 | clinicaltrials |
| NCT05286229 | A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan | active not recruiting | Phase 1 | 8 | AbbVieINDUSTRY | 1 | Aug 8, 2025 | clinicaltrials |
| NCT02899052 | Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) | active not recruiting | Phase 2 | 120 | AbbVieINDUSTRY | 5 | Aug 5, 2025 | clinicaltrials |
| NCT05860036 | A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma | active not recruiting | Phase 2 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06944119 | Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia | active not recruiting | — | 250 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jul 28, 2025 | clinicaltrials |
| NCT07088783 | Mobile App Education Based on Orem's Self-Care Model in Multiple Myeloma Patients(OCARE-MM) | active not recruiting | N/A | 60 | OzlemOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT04052880 | Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM | active not recruiting | Phase 2 | 17 | Larysa SanchezOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06220097 | Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies | active not recruiting | Phase 2 | 28 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT05123131 | Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma(Isa-RVD) | active not recruiting | Phase 2 | 54 | Cancer Trials IrelandNETWORK | 2 | Jul 8, 2025 | clinicaltrials |
| NCT07046182 | Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight | active not recruiting | Phase 4 | 34 | Zhengzhou UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT03421132 | Multiple Myeloma Molecular Monitoring Study(M4) | active not recruiting | — | 96 | Horizon Health NetworkOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT06024694 | Primary Mediastinal Large B-cell Lymphoma With CNS Involvement | active not recruiting | — | 45 | IRCCS San RaffaeleOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT03817320 | PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | active not recruiting | Phase 1 / Phase 2 | 24 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Jun 17, 2025 | clinicaltrials |
| NCT03190525 | Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma(CLARITY) | active not recruiting | — | 530 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 2 | Jun 12, 2025 | clinicaltrials |
| NCT06742879 | A Multi-center Clinical Study of Zanubrutinib in Combination With First-line Chemoimmunotherapy in Patients With Grade 3A High-risk Follicular Lymphoma(ZCM3AHRFL) | active not recruiting | — | 37 | Zhengzhou UniversityOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT03995147 | Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma | active not recruiting | Phase 2 | 51 | University of ChicagoOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06541665 | Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL | active not recruiting | Phase 1 | 20 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT04668690 | Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL | active not recruiting | Phase 3 | 193 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | May 31, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Oct 15, 2025source: clinicaltrials